Kemp Proteins, LLC
Frederick, MD Doing business as Kempbio
- UEI
- JMLEB78WL8B4
- CAGE
- 5BCT2
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Partnership or Limited Liability Partnership
- NAICS codes registered in SAM.gov
-
- 541714 Research and Development in Biotechnology (except Nanobiotechnology) Primary
- 325413 In-Vitro Diagnostic Substance Manufacturing
- 325414 Biological Product (except Diagnostic) Manufacturing
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration date
- Physical address
- 5119 Pegasus Ct p, Frederick, MD 21704, USA
- Website
- kempproteins.com
- Founded
- 2008
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Hybridoma production | Defense Health Agency | $40,000 | |
| Gene synthesis, cloning and plasmid generation services | National Institute of Allergy and Infectious Diseases | $119,790 | |
| Gene expression services for universal influenza vaccine studies (ambis #2176187) | National Institute of Allergy and Infectious Diseases | $15,459 | |
| Monoclonal antibody production | Food and Drug Administration | $34,122 | |
| Transient expression screening | National Institute of Allergy and Infectious Diseases | $9,463 |
About Kemp Proteins, LLC
Kemp Proteins, LLC, doing business as Kempbio, is a Frederick, Maryland-based small disadvantaged business manufacturer that specializes in gene-to-protein bioservices and biological research support. The company is registered in SAM.gov as a partnership or limited liability partnership and provides a comprehensive range of services to support federal biomedical research, vaccine development, and infectious disease studies. Kempbio has established itself as a reliable provider of specialized immunological materials and laboratory services to multiple federal agencies, leveraging expertise across protein expression, gene synthesis, molecular cloning, monoclonal antibody production, and viral-like particle production.
Kempbio's prime federal contract awards demonstrate extensive experience delivering sophisticated biological services across multiple government agencies. The company has received purchase orders and delivery orders from the National Institute of Allergy and Infectious Diseases (NIAID) totaling approximately $61,000 for gene synthesis, cloning, plasmid generation, gene expression screening, construct design, and baculovirus production services, with performance periods spanning from 2021 through 2023. The Food and Drug Administration awarded Kempbio approximately $95,600 in purchase orders for monoclonal antibody production and baculovirus protein expression services, with the monoclonal antibody production contract designated as a total small business set-aside with performance extending through September 2027. The National Institute of Dental and Craniofacial Research awarded a $28,200 purchase order for production, purification, and analysis of viral-like particle services. Most recently, the Defense Health Agency issued a $40,000 delivery order on August 1, 2025, for hybridoma production services scheduled for completion by September 28, 2026. Additionally, Kempbio has served as a subcontractor to prime contractors Battelle Memorial Institute and Mriglobal, performing gene synthesis, cloning, and recombinant protein manufacturing work supporting specialized biodefense and research initiatives. The cumulative value of Kempbio's documented prime contracts exceeds $300,000, reflecting the company's consistent performance across multiple federal research programs.
Kempbio holds a significant single-award Blanket Purchase Agreement (BPA) with the Office of Logistics and Acquisition Operations valued at up to $10,000,000, with a period of performance through August 31, 2026. This BPA, awarded on August 1, 2023, was structured to facilitate recurring procurement of biological materials, animal testing services, and laboratory and testing services on an as-needed basis through task order issuance. The BPA represents Kempbio's most substantial federal contract vehicle and underscores the company's capacity to support sustained biomedical research programs across federal agencies. The agreement's broad scope covering biological materials and comprehensive testing services aligns with Kempbio's core competencies in gene-to-protein bioservices and positions the company as a standing source for federal agencies requiring specialized biological research support and materials on a recurring basis.
Quick answers
What is Kemp Proteins, LLC's UEI?
Kemp Proteins, LLC's Unique Entity ID (UEI) in SAM.gov is JMLEB78WL8B4.
What is Kemp Proteins, LLC's CAGE code?
Kemp Proteins, LLC's CAGE code is 5BCT2.
What is Kemp Proteins, LLC's primary NAICS code?
Kemp Proteins, LLC's primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Kemp Proteins, LLC located?
Kemp Proteins, LLC's physical address in SAM.gov is 5119 Pegasus Ct p, Frederick, MD 21704, USA.
Is Kemp Proteins, LLC registered in SAM.gov?
Yes. Kemp Proteins, LLC's SAM.gov registration is active through June 11, 2027.
What is Kemp Proteins, LLC's most recent federal award?
Kemp Proteins, LLC's most recent federal contract award is Hybridoma production (HT942525FE003), from Defense Health Agency, on August 1, 2025.
On GovTribe
See Kemp Proteins, LLC's full federal record
- Federal contract awards
- IDV awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors